Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Maze Therapeutics, Inc. ( (MAZE) ) has provided an update.
On February 4, 2026, Maze Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200 million, with an initial $40 million tranche funded on the same date and net proceeds of approximately $38.4 million. The facility, maturing on February 1, 2031, is structured into multiple additional tranches available over up to 60 months subject to financial, performance and financing milestones, and carries a floating interest rate tied to the prime rate with specified floors, interest-only payments for up to 48–60 months, prepayment premiums, and tiered exit fees. The loan is secured by a first lien on substantially all of Maze’s assets and imposes customary affirmative and negative covenants, including minimum cash requirements tied to the company’s market capitalization, and provides for customary events of default that could accelerate repayment. In connection with this new facility, Maze terminated its prior Loan and Security Agreement with Banc of California effective February 2, 2026, and the bank’s security interest in the company’s assets was released, signaling a strategic refinancing and strengthening of Maze’s liquidity position under a larger, more flexible debt structure.
The most recent analyst rating on (MAZE) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Maze Therapeutics, Inc. stock, see the MAZE Stock Forecast page.
Spark’s Take on MAZE Stock
According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.
The score is primarily driven by improving financial performance (strong 2024 profitability and cash flow with low leverage) and supportive technical momentum (price above major moving averages and positive MACD). This is tempered by weaker valuation clarity due to a negative P/E and no dividend yield data.
To see Spark’s full report on MAZE stock, click here.
More about Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a biotechnology company focused on developing therapeutics, with operations financed in part through structured debt facilities, reflecting its capital-intensive research and development activities in the life sciences sector.
Average Trading Volume: 445,119
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.24B
Learn more about MAZE stock on TipRanks’ Stock Analysis page.